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Abstract
Background: Major depressive disorder is a common debilitating illness that is the second leading contributor to the
global burden of disease. Unfortunately, about 30 % of patients do not respond to adequate trials of antidepressants
and/or psychotherapies. About 45–60 % of such treatment-resistant patients will remit with electroconvulsive therapy
(ECT). However, relapse rates are high following ECT—38 % after 6 months. There is a need for better relapse
prevention strategies. One possibility is to use ketamine, a competitive glutamate receptor antagonist used for
anaesthesia. A recent paradigm shift in treating depression and understanding its biology has been the finding that
ketamine has a robust, rapid-onset, though short-lived, antidepressant effect that is possibly mediated through
neuroplastic effects. However, ketamine has not previously been reported on for relapse prevention.
Methods/design: The main objective of this study is to conduct a randomised controlled pilot trial (n = 40) of
a 4-week course of once-weekly ketamine infusions for relapse prevention following ECT for depression to
assess trial procedures that will inform a future definitive trial. Participants with unipolar depression will be
recruited prior to commencing ECT and be assessed weekly during the ECT course using the primary clinical
outcome, the 24-item Hamilton Rating Scale for Depression (HRSD-24). Those who meet standard response
criteria will be invited, on completing ECT, to be randomised in a 1:1 ratio to a course of four once-weekly
infusions of ketamine or an active comparator midazolam, which mimics some of the effects of ketamine and
may improve blinding over inactive placebo. Participants will be followed up over 6 months using the HRSD-24 to
assess for relapse.
Discussion: This is the first registered trial (NCT02414932, https://clinicaltrials.gov/ct2/show/NCT02414932) of ketamine
for depression relapse prevention, an important possible use of this agent. The primary focus of the pilot trial is on
feasibility. However, a 95 % confidence interval will be determined for the difference between ketamine and
midazolam groups in 6-month relapse rates to help inform a future definitive trial.
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Background
Depression, ECT and relapse
Major depressive disorder (MDD) is a debilitating men-
tal illness with a lifetime prevalence of 12–20 % [1]. It is
the most costly brain disorder in Europe, accounting for
1 % (€118 billion annually) of the total European econ-
omy [2]. Indeed, depression is currently the second
largest cause globally for years lived with disability [3].
About 30 % of patients do not respond to antidepres-
sants even after multiple trials with/without psychother-
apies [4]. However, electroconvulsive therapy (ECT)
offers up to 60 % of such treatment-resistant patients to
complete remission [5–7]. ECT is a medically safe pro-
cedure and is more acutely effective than psychotherapy
or antidepressants for severe, often treatment-resistant,
depression [5]. The major concerns are cognitive side
effects, but for most people, these are transient and
many cognitive functions improve [8]. Treatments in-
volve passing small electrical charges through the brain
to induce a seizure lasting ~30 s under anaesthesia with
a muscle relaxant. Six to 12 treatments are typically ad-
ministered in a course, two to three times weekly [9].
Worldwide, 1.4 million people receive ECT annually,
including nearly 260 people in Ireland [10].
In a recent meta-analysis, we found that taking antide-
pressants following successful ECT halves the risk for re-
lapse (risk ratio = 0.49, p < 0.0001, NNT = 3.3) at 6 months
from nearly 80 % [11], but mean relapse rates remain high:
27.1 % after 3 months and 37.7 % after 6 months [11].
Even continuation ECT (C-ECT), albeit mostly at non-
adjustable fixed schedules, does not seem to improve
6-month relapse rates (37.2 %). Notably, these relapse
rates are similar to those for patients who respond only
after ≥3 antidepressant steps and most likely reflect the
recurrent nature of treatment-resistant depression [4].
A major challenge now is how best to prevent relapse
after successful treatment of depression with ECT. How-
ever, remarkably, the evidence base for relapse preven-
tion in depression following any successful treatment is
small. For example, the National Institute for Health and
Care Excellence (NICE) in the UK have identified that
evidence on relapse prevention in depression is limited
and recommended research in this area. [12] To date,
the reported randomised controlled trials for relapse
prevention following successful antidepressant therapy
have focused on the effect of 12 months’ tricyclic or
SSRI antidepressant therapy, showing consistent but lim-
ited reduction in relapse rates [13]. As discussed in our
review [11], there have been very few randomised, con-
trolled trials focusing on relapse prevention after ECT.
One study investigated the use of nortriptyline or nor-
triptyline and lithium for relapse prevention following
successful ECT for depression [14]. Nortriptyline-lithium
combination therapy had a marked advantage in time to
relapse, superior to both placebo and nortriptyline alone.
Other studies have focused on fixed-schedule continu-
ation ECT, which has a relapse prevention effect in well-
chosen groups [15].
Ketamine as an antidepressant
Ketamine is a competitive glutamate N-methyl-D-aspar-
tate receptor (NMDAR) antagonist with a half-life of
2–3 h. Ketamine has a remarkably rapid antidepressant
effect, targeting core symptoms, in treatment-resistant
depression when given as single sub-anaesthetic doses,
usually a 40-min 0.5 mg/kg intravenous infusion [14].
Thereafter, robust antidepressant effects (~70 % re-
sponder rates) occur within 2–4 h and persist for a few
days, i.e. beyond immediate NMDAR blockade [14].
These findings have led to the most exciting develop-
ment in treating and understanding depression in over
50 years and represent a paradigm shift away from con-
ventional slow-acting monaminergic antidepressants.
Preclinical studies have shown that within just 2 h,
ketamine increases synaptogenesis and spine formation
in rodent prefrontal cortex and rapidly reverses chronic
stress-induced depressive behaviours and prefrontal
neuronal atrophy [15]. These effects are mediated, at
least in part, via Akt/GSK-3/mammalian target of rapa-
mycin (mTOR) signalling and increased dendritic
translation of synaptic proteins [16], as well as deactiva-
tion of eukaryotic elongation factor 2 (eEF2) kinase,
resulting in de-suppression of brain-derived neurotrophic
factor (BDNF) translation [17]. BDNF mediates synaptic
plasticity and is implicated in mechanisms of antidepres-
sants and ECT [18]. Changes in blood mononuclear cell
levels of phosphorylated mTOR, eEF2 and GSK-3beta
have also been associated with response to ketamine [19],
suggesting potential as biomarkers for response.
Ketamine is psychotomimetic, but at low dosage, it is
safe, with patients and healthy controls occasionally
experiencing mild dissociative and psychotic symptoms
that resolve soon after finishing infusions [16–18]. To
control for these effects, and also avoid “carry-over” ef-
fects in crossover studies while improving blinding, mid-
azolam, at the sub-anaesthetic dose of 0.045 mg/kg, has
been used as a control in parallel-group design trials
rather than inactive placebo saline [19]. Ketamine can be
a drug of abuse and chronic high-dose abuse can cause
uropathy and dependency. However, repeated (e.g. 2–3/
week for 2 weeks) infusions of sub-anaesthetic ketamine
are safe with more sustained antidepressant effects [20,
21]. Two recent reviews of trials of ketamine for use as
an antidepressant showed the most commonly used
dosage is a 40-min infusion of 0.5 mg/kg [16, 22]. Bio-
availability of ketamine is highest when administered
intravenously [23]. In sub-anaesthetic doses, ketamine
is a medically safe drug but can cause transient rises in
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pulse and blood pressure during infusion and for up to
80 min afterward. However, a recent review of ketamine
in depression concluded that outside recreational usage,
there have been no reports of persistent adverse effects
with sub-anaesthetic uses of ketamine [24].
The effect of ketamine on cognition is unclear and has
only been studied in acute treatment of depression [25].
There may be changes in visual and working memory
[26] and an association between baseline neurocognitive
performance and response to ketamine [27]. Optimum
dosing and deliver of ketamine has not been established
[25]. Ketamine has been used for ECT anaesthesia and is
associated with earlier improvement and possibly fewer
cognitive side effects but no overall better response [16,
20, 22, 28]. There have been insufficient studies of intra-
muscular, oral or intranasal ketamine for depression to
currently warrant studying these preparations for relapse
prevention [21]. While the half-life of ketamine is 3 h, in
previous studies, the antidepressant effect was main-
tained for up to 2 weeks [29]. No trials have yet been
reported, or registered, for using ketamine as an adjunct-
ive treatment to reduce relapse rates following successful
depression treatment—a potential use of ketamine that
this trial will explore.
Methods/design
Study objective
The primary objective is to conduct a randomised, con-
trolled, patient- and rater-blinded pilot study of ketamine
vs. an active comparator (midazolam) for 4 weeks follow-
ing successful ECT, to assess trial process to inform a
future definitive trial.
Secondary objective
To calculate a 95 % confidence interval for an unadjusted
hazard ratio that will allow interpretation of statistical
difference between ketamine and midazolam groups to
assess ketamine for reducing 6-month relapse rates fol-
lowing successful ECT.
Overview
This randomised, controlled pilot trial will take place
over 30 months. The study will have an open recruit-
ment phase (phase I) followed by a randomised treat-
ment phase (phase II). We will initially recruit patients
with unipolar major depressive disorder (Diagnostic
and Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV) criteria [30]) referred for ECT, who
will be assessed weekly to identify those eligible to take
part in the randomised controlled pilot trial in phase
II. Participants who are successfully treated with ECT
(phase 1) and continue to meet inclusion criteria will
be randomly allocated in a 1:1 ratio to a 4-week course
of either once-weekly ketamine at 0.5 mg/kg or the
active comparator midazolam at 0.045 mg/kg (phase 2).
The trial will take place under “real world” conditions with
both groups continuing usual care (e.g. regular medica-
tions, psychological and other therapies and out-patient
review) during the randomised treatment phase and there-
after. Participants will be followed up over 6 months
following ECT to identify if and when relapse occurs.
Site
This single-site study will take place in St. Patrick’s
University Hospital, Dublin, an independent-sector 250-
bed university teaching hospital that provides a national
mental health service. About one third of all ECT in
Ireland is administered at the centre [7, 31].
Research ethics approval
Approval for this pilot trial was obtained from the joint
authorised Research Ethics Committee of St. James’ and
Tallaght Hospitals, Dublin. Site approval was also obtained
from the relevant committee at St. Patrick’s University
Hospital. Authorisation for the clinical trial was obtained
from the Health Products Regulatory Authority of Ireland,
the relevant body under the European framework for clin-
ical trials, EudraCT (2014-000339-18). The study will be
conducted in accordance with the principles that have
their origin in the Declaration of Helsinki [32], in ac-
cordance with Good Clinical Practice (GCP), as defined
by the International Conference on Harmonisation [33]
(ICH), and in accordance with the ethical principles
underlying European Union Directive 2001/20/EC and
2005/28/EC. The trial has been registered at clinical-
trials.gov (NCT02414932).
Recruitment
In line with recommendations for pilot studies [34], a
formal sample size calculation has not been performed.
Twenty participants is an acceptable total number for the
purposes of a pilot trial. For this pilot trial, we aim to
recruit up to 20 patients per group, a total of 40. Response
rates to ECT are 40–60 % [5], so at least 66 patients need
to be initially recruited. Allowing for a 15 % drop-out rate,
we will therefore seek to recruit 78 patients. We expect to
recruit 78 participants within 16 months, 47 of whom will
meet response criteria following ECT [5], and that 40 of
these will additionally consent to be randomised and
participate in the pilot trial.
Consent
Written informed consent will be obtained by members
of the research team using the study-specific consent
form (Additional file 1). Potential participants will be
provided with an information leaflet and letter of invita-
tion (Additional file 1) and verbal information at the first
point of contact with a member of the research team.
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Eligibility criteria
Participants will be current inpatients in university teach-
ing hospitals in St. Patrick’s Mental Health Services, who
have a diagnosis of unipolar MDD and are referred for
ECT. Participants may be male or female, aged ≥18 years,
and from a variety of geographical (within Ireland) and
socioeconomic backgrounds. Participants will not have
any medical condition that would preclude treatment with
ECT or ketamine/midazolam.
To be eligible for inclusion in phase 1, each participant
must meet each of the following criteria at screening
and must continue to fulfil these criteria at baseline.
1. Subjects must be able and willing to give written
informed consent and comply with the requirements
of this study protocol.
2. Diagnosed with unipolar major depressive disorder
(DSM-IV), have a 24-item Hamilton Rating Scale
for Depression (HRSD-24) of ≥21 and be referred
for ECT.
3. Female subjects of child-bearing potential and male
subjects whose partner is of child-bearing potential
must be willing to ensure that they or their partner
use effective contraception during the randomised
treatment phase (phase II) and for 5 weeks
thereafter.
Subjects are excluded from the study if any of the
following criteria are met at screening:
1. Allergy/sensitivity to study medications or their
ingredients.
2. Subjects who have participated in another study and
received any other investigational agent within
6 months.
3. Any condition rendering patient medically unfit for
ECT; general anaesthesia; ketamine or
midazolam—assessed by physical examination,
routine haematology and biochemistry investigations
prior to enrolment.
4. Medications that may significantly alter the
pharmacokinetics of ketamine (e.g. ketoconazole,
clarithromycin) are contraindicated during the trial,
and participants taking any of these medications at
screening will be excluded from the trial.
5. Subjects who have a history of drug or alcohol use
that, in the opinion of the investigator, would
interfere with adherence to study requirements.
6. Known history of, or documented positive hepatitis
B or C or HIV infection, advanced malignancy or
terminal illness.
7. Scheduled for non-trial procedures requiring general
anaesthesia during the study.
8. Active suicidal intention.
9. Dementia, intellectual disability or a score on the
standardised Mini Mental State Examination
(sMMSE) of <24.
10. Lifetime history of bipolar affective disorder.
11. Current history of post-traumatic stress disorder.
12. Other axis I diagnosis (DSM-IV).
13. ECT in the 6 months prior to recruitment.
14. Currently a prisoner or residing in a nursing home.
For inclusion in the randomised controlled trial (phase
2), following successful ECT, patients must additionally
have:
1. Received a significant course of ECT (i.e. at least five
sessions)
2. Achieved at least response criteria (i.e. ≥60 %
decrease from baseline HRSD-24 score and score
≤16 on two consecutive weekly ratings)
3. Have a nominated adult who can stay with them for
24-h on out-patient treatment days
4. sMMSE [35] score of ≥24
Assessments
The primary clinical outcome measure is the relapse rate
at 6 months as measured using the objectively rated
HRSD-24 [36]. To enter the study, patients must score
≥21. Subjective mood ratings will be also measured
using the Quick Inventory of Depressive Symptoms,
self-report version (QIDS-SR) [37]. Baseline assessment
will also include diagnosis and treatment history: diagno-
sis of major depressive disorder will be confirmed using
the mood episodes module of the Structured Clinical
Interview for DSM-IV Axis I Disorders (SCID) [38]. The
Maudsley Staging Method for Treatment Resistant
Depression (MSTRD) [39] will be used to provide a
measure of treatment-resistance. Handedness will be re-
corded with the Edinburgh Handedness Questionnaire
(EHQ) [40]. The National Adult Reading Test (NART)
[41] will measure premorbid intelligence.
Additional baseline data from patient interview and
case-note review will include age, sex, weight, height,
occupation, educational attainment, duration of index
depressive episode, number of previous depressive epi-
sodes, previous ECT, history of medical illness and surgical
treatments, personal and family history of alcohol/sub-
stance dependency, presence of psychotic symptoms
(detected by SCID) and current medications and other
therapies. Changes in medications will be documented
at follow-up interviews (Table 1, schedule of events).
Participants will be assessed weekly during ECT using
the HRSD-24 and QIDS-SR. Response to ECT is defined
as achieving ≥60 % decrease from baseline HRSD-24
and score ≤16 on two consecutive weekly ratings. Remis-
sion criteria are ≥60 % decrease in HRSD from baseline
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and score ≤10 on two consecutive weekly ratings. Those
identified as being ECT responders will be invited to
participate in the two-group parallel-design randomised
controlled pilot trial. The advantages of randomisation
and blinding in this group will also be used to perform
studies of peripheral blood biomarkers as potential pre-
dictors of response to ketamine (Additional file 2). During
infusion sessions in the randomised treatment phase,
HRSD-24 scores will be obtained 60 min before the infu-
sion begins and at +120 and +240 min afterwards. Base-
line scores on sleep and appetite items will be maintained
for repeated measures within 1 day. The +240 min HRSD-
24 scores will serve as the weekly post-ECT scores up to
follow-up week 4.
Ketamine psychotomimetic effects and adverse events
will be assessed using the following instruments before,
during (+35–40 min) and after (+240 min) infusions of
ketamine or midazolam:
 Clinician-Administered Dissociative States Scale
(CADSS) [42]
 Brief Psychiatric Rating Scale (BPRS; four-item
positive symptom subscale) [43]
 Young Mania Rating Scale (YMRS; mood item) [44]
 Patient-Rated Inventory of Side Effects (PRISE) [45]
Participants will be followed up for 6 months following
ECT with repeated questionnaires comprising treatment
review plus HRSD-24 and QIDS-SR at weeks 6, 8, 12
and 20 post-ECT. Criteria for relapse are ≥10 point in-
crease in HRSD-24 compared to baseline phase 2 score
plus HRSD ≥16; in addition, increase in the HRSD
should be maintained 1 week later (if indicated, add-
itional follow-ups will be arranged). Hospital admission,
further ECT and deliberate self-harm/suicide also consti-
tute relapse. Timing of these events will be recorded. A
final follow-up session in week 26 will comprise HRSD-
24, QIDS-SR and cognitive outcomes.
There are no published data on effects of ketamine on
cognition in ECT responders. We will use the following
battery pre- and post-ECT course, after the fourth infusion
and at 6 -month follow-up. The post-ECT assessment will
Table 1 Schedule of enrolment, assessments and interventions














Background, SCID, NART, CTQ ✓
Treatment review ✓ ✓ ✓ (1–4) ✓ (6–20) ✓
Clinical outcomes
HDRS-24 ✓ ✓ ✓ ✓✓✓✓ (1–4) ✓ (6–20) ✓
QIDS-SR ✓ ✓ ✓ ✓✓✓✓ (1–4) ✓ (6–20) ✓
Cognitive outcomes
ACE-R ✓ ✓ ✓4th ✓
Digit spans ✓ ✓ ✓4th ✓
Trails A + B ✓ ✓ ✓4th ✓
sMMSE ✓ ✓ ✓4th ✓







Signed consent ✓ ✓
Verbal assent ✓ ✓ ✓ ✓✓✓✓ (1–4) ✓ (6–20) ✓
Eligibility
Eligibility check ✓ ✓ ✓ ✓ ✓✓✓✓ (1–4) ✓ (6–20) ✓
Randomisation
Allocation ✓
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serve as baseline for the randomised pilot trial. Where ap-
propriate, parallel versions will be used to reduce practice
effects. Global cognition will be assessed with the sMMSE
[35]. Immediate short-term memory, attention and work-
ing memory will be measured using Forward and Back-
ward Digit Spans [46]. Motor and psychomotor speed will
be assessed using the Trail Making Test (part A) [46].
Frontal-executive function will be rated by Trail Making
Test (part B) [46] plus letter and category verbal fluencies
[47]. Anterograde verbal memory will be tested using the
verbal learning component of the Addenbrooke’s Cogni-
tive Examination III (delayed and immediate recall of a
seven-item address) [48]. Retrograde amnesia for autobio-
graphical information will be measured using the Kopel-
man Autobiographical Memory Interview (K-AMI) [49].
Interventions
Participants in phase I will receive ECT and usual care
and will be monitored weekly using the HRSD-24 for re-
sponse. ECT will be administered twice-weekly with
hand-held electrodes according to Royal College of Psy-
chiatrists’ guidelines and as previously described [7, 50].
Briefly, the Mecta 5000 M device (Mecta Corporation,
USA) will be used and seizure duration measured by
EEG monitoring. Methohexitone (0.75–1.0 mg/kg) will
be used for anaesthesia with suxamethonium (0.5–
1.0 mg/kg) as muscle relaxant. Brief-pulse (1.0-ms pulse
width; current amplitude 800 mA) ECT will be adminis-
tered twice weekly (Mecta 5000 M device, Mecta Corp.,
Portland, Ore.; maximum 1200 mC), using methohexi-
tone (0.75–1.0 mg/kg) anaesthesia and succinylcholine
(0.5–1.0 mg/kg) for muscle relaxation (16, 22). Seizure
threshold (ST) will be established by a method of limits,
as previously described [7], at the first session, and sub-
sequent treatments will be given at 1.5 × ST for BL ECT
and 6.0 × ST for RUL ECT. Stimulus charge will be ti-
trated upward as required during treatment courses fol-
lowing a standard stimulus dosing protocol. To reflect
routine clinical practice, number of ECT treatments will
be determined by referring physicians who will be blind
to randomisation. ECT characteristics will be recorded.
Participants who have successfully responded to ECT
in phase I and meet inclusion criteria to continue to
the randomised controlled pilot trial in Phase II will be
randomised (1:1) to receive four once-weekly infusions
of either ketamine or midazolam. The regimen of four
weekly infusions was chosen to facilitate subjects trav-
elling for appointments and because ketamine has
proven effects as a rapid-acting antidepressant but has
not yet been studied as a series of infusions for relapse
prevention. Patients and raters will be blind to treat-
ment. The first infusion will be administered within
2 weeks of completing ECT and may be administered
as an inpatient or outpatient; further infusions will take
place as an outpatient. Each infusion will take 40 min,
and monitoring will take place for 200 min post-
commencement of infusion. Ketamine hydrochloride
10 mg/ml infusion at 0.5 mg/kg (Pfizer Healthcare
Ireland) or midazolam hydrochloride (Hypnovel) 10 mg/
5 ml solution at 0.045 mg/kg (Roche Products Ireland
Ltd) will be made up as 50 ml colourless saline solutions
and administered intravenously via an infusion pump.
This dose and administration was chosen based on a pre-
vious randomised controlled trial of ketamine and mid-
azolam in which these dosages were well-tolerated [51].
During each treatment session, participants will be
monitored for heart rate, blood pressure, pulse oximetry
and electrocardiogram changes. Adverse or psychoto-
mimetic effects of either agent will be monitored using
the CADSS, BPRS (four-item positive symptom sub-
scale), YMRS (mood item) and the PRISE administered
before, during and after infusions. Cognitive outcomes
will be repeated in week 4. All other assessment mea-
sures will be repeated weekly, including treatment re-
view, HRSD-24 and QIDS-SR.
Participants will be advised not to drive or operate
heavy machinery for 24 h post-commencement of infu-
sions and be provided with information on recent
changes to the Road Traffic Act (Ireland) 2014, which
includes provisions for roadside intoxication testing. Par-
ticipants will be asked to ensure they have a nominated
adult who can stay with them for 24 h on outpatient
treatment days and will be contacted by a researcher
24 h after each session to enquire about side effects.
Treatment-as-usual will continue during the trial. Par-
ticipants will continue to receive pharmacotherapy, psy-
chotherapy or other therapeutic inputs as recommended
by their treating team for the duration of the trial. There
are no provisions for post-trial care or improving adher-
ence due to the pilot trial design. Premature termination
of the trial may take place in the event of new informa-
tion regarding safety of investigative medicinal products
becoming available, unsatisfactory progression of the
trial, major breach of data confidentiality or if in the par-
ticipants’ best interests. Subjects have the right to volun-
tarily discontinue study treatment or withdraw from the
study at any time for any reason without any conse-
quences. Subjects must discontinue the investigational
medicinal product(s) and be withdrawn from the study
for any of the following reasons:
 Withdrawal of consent by the subject
 Any medical condition that the investigator or
sponsor determines may jeopardize the subject’s safety
if she or he continues receiving the study treatment
 Pregnancy
 Ineligibility (either arising during the study or
retrospectively having been overlooked at screening)
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 An adverse event which requires discontinuation of
the study medication
 Treatment failure and disease progression
 Lack of compliance with the study and/or study
procedures (e.g. dosing instructions, study visits)
 Loss to follow-up—at least three documented
attempts must be made to contact any subject lost
to follow-up.
Outcomes
The focus of this study is on trial process with assess-
ment of the primary clinical outcome being secondary.
However, efficacy data will be collected in the course of
the trial and will be reported as part of the study
findings.
Process outcomes that will help to inform a future de-
finitive ketamine relapse prevention trial include infor-
mation on the following:
1. Recruitment methods and rate
2. Willingness of participants to be randomised
3. Willingness of participants to complete assessments
4. Randomisation
5. success of blinding of participants and raters
6. Ability to administer a course of four weekly
ketamine infusions
7. Medical safety and acceptability of ketamine
infusions in an ECT responder population
8. Rates of adverse dissociative and psychiatric events
9. Adherence to allocated treatment
10. Adherence to follow-up
11. Reasons for drop-out from treatment
12. Reasons for drop-out from follow-up
13. A 95 % confidence interval for the difference
between the ketamine and midazolam groups in
6-month relapse rates to help inform a future
definitive trial
The primary outcome relating to efficacy (the assess-
ment of which is not a primary objective) is the relapse
rate at 6 months as measured by HRSD-24. Subjective
mood rating as measured by scores on QIDS-SR is a sec-
ondary efficacy outcome. The following safety evalua-
tions will be performed during the study: adverse event
monitoring, vital signs, cognitive and clinical assess-
ments. Safety endpoints are:
(i) Tolerability of ketamine vs. midazolam in terms of
cognitive outcomes
(ii) Tolerability of ketamine vs. midazolam in terms of
psychotomimetic effects as measured by scores on
CADSS, BPRS, YMRS and PRISE
(iii)Number of adverse effects in ketamine vs.
midazolam groups
This trial has been designed and will be reported in
line with the Consolidated Standards of Reporting Trials
(CONSORT) guidelines [52] (Fig. 1).
Allocation sequence generation and concealment
ECT responders will be randomised after post-ECT as-
sessment. Subjects will be randomly assigned to one of
Approach patients referred for ECT and screen for 
eligibility.  Expect 170 referrals over 16 months. 
Excluded (n=92)
Allocated to ketamine, up to 4 once  
weekly infusions (n=20); intra-treatment  
questionnaires
Follow-up questionnaires, up to 
6 months after end of ECT 
Allocated to midazolam, up to 4 once  





Recruit 78 to open study, of 
which 47 will be responders.
40 consent to randomisation.
Drop-out (n=7)
Follow-up questionnaires, up to 











Fig 1 Consort diagram
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two treatment groups in a 1:1 ratio. Computerised ran-
dom allocation, using randomly permuted blocks, will be
done independently by the Centre for Support and
Training in Analysis and Research (CSTAR, University
College Dublin, www.cstar.ie). Allocation information
will be provided by means of a randomisation list pre-
pared by CSTAR, available only to the anaesthetist to
ensure allocation concealment. Researchers involved in
ratings will not have access to information regarding
treatment allocation.
Blinding and unblinding
To ensure patient safety during infusions and in the
post-infusion period, the anaesthetist administering the
ketamine/midazolam infusions will not be blinded but
he will not be involved in assessments or data analysis.
Patients, raters and the trial statistician will remain
blinded. Success of blinding for patients and raters will
be assessed after the first treatment. A set of envelopes
containing allocation information will remain unopened
but may be used where emergency unblinding is indi-
cated. Unblinding for one or all participants will take
place if it is in the best interests of the participants.
Statistical methods
Pilot trial data will be analysed on an intention-to-treat
basis for all participants who complete at least one infu-
sion and one post-infusion evaluation. Data analyses will
be performed blinded to allocation by the trial statistician.
As this is a pilot trial and small numbers of participants
are involved, no missing values will be imputed. Data will
be analysed using IBM PASW (SPSS) version 22 and “R”
(R Foundation for Statistical Computing, Austria).
Demographic and baseline data will be summarised for
each treatment group by presenting descriptive statistics.
Descriptive statistics will also be used to report: rates of
recruitment, willingness to be randomised, willingness to
complete assessments, medical/cognitive/psychotomim-
etic/general adverse events between groups, adherence
to allocated treatments, adherence to follow-up between
groups and reasons for drop-outs between groups.
Relapse-free survival times will be compared between
groups using Kaplan-Meier survival curves and log-
rank test. As this is a pilot trial and insufficiently pow-
ered to achieve statistical significance, there will be no
formal comparison of the two treatment groups in the
pilot trial. However, Cox proportional hazard regression
analysis will provide a 95 % confidence interval for an
unadjusted hazard ratio for a future definitive trial.
As this is a pilot trial and small numbers of partici-
pants are involved, no missing values will be imputed.
As per the pilot trial design, the primary outcomes are
those relating to reasons for dropout and these will be
presented using descriptive statistics.
Data management
A trial-specific operating procedure for data quality
assurance will be followed by all researchers and in-
volves eight levels of quality assurance. Researchers will
be trained in administration of the primary assessment
tool used in this study, the HRSD-24, and training will
be repeated every 6 months to ensure good inter-rater
reliability. The study will comply with the Data Protec-
tion (Amendment) Act, 2003, Ireland. All documents
will be stored safely in a designated locked filing cabinet
in a locked office within the Research Building at St.
Patrick’s University Hospital, and confidentiality will be
observed at all times. With the exception of the informed
consent form, subjects will be referred to only by their
subject identification number on all study-specific docu-
ments, whether hard copies or electronic. Data analysis
will take place in another facility (CSTAR, University
College Dublin), and data will be anonymised prior to se-
cure transfer to CSTAR for analysis.
Trial management
The Trial Steering Committee, chaired by an independent
clinician and including a service user representative, will
meet on a six-monthly basis. The Trial Management
Group, comprising trial researchers, will meet on a weekly
basis. A Data Monitoring Committee (DMC), chaired by
an independent clinical researcher and comprising an
independent biostatistician and independent trial method-
ologist, will meet every 6 months to review blinded data
and reports prepared by the trial statistician. The trial
results will be published and communicated to partici-
pants, and authorship eligibility guidelines of the Inter-
national Committee of Medical Journal Editors (ICJME)
will be followed. There is no intended use of professional
authors. Important amendments to the trial protocol will
be communicated to all relevant agencies. The sponsor
owns the final dataset; access will be managed through the
Principal Investigator. There are no contractual agree-
ments limiting access to data for investigators. There are
no plans to grant public access to the participant-level
dataset or statistical code. Trial processes will not be inde-
pendently audited due to the pilot trial design.
Discussion
This is the first registered trial investigating the potential
use of ketamine for relapse prevention in depression and
the first study to investigate intravenous ketamine for re-
lapse prevention following successful response to ECT.
Only one other registered study proposes to investigate
this issue; however, that study uses intranasal esketamine
(NCT02493868). Previous studies have shown that keta-
mine has a rapid effect in acute depression, maintained
up to 2 weeks, but repeated infusions have not been
studied in a recovered population for the purpose of
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relapse prevention. The focus of this pilot trial is on
process outcomes to help inform a future definitive trial.
Strengths of the study include its double-blind design
and use of independent randomisation. Notwithstanding
the potential utility of the trial in assessing the safety
and practicability of this treatment protocol, there are
some limitations. The small number of proposed partici-
pants in this pilot trial (up to n = 40) limits the statistical
analyses which can be confidently applied to the ones
described here. The nationwide catchment area of the trial
site may pose difficulties in retention of participants from
phase I to phase II due to travel challenges. Treatment-as-
usual will continue for all participants during the pilot
trial, resulting in a heterogeneous participant group. This
pragmatic design will, however, improve generalisability of
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